8-K: Clearside Biomedical Delists from Nasdaq, Enters Bankruptcy

Clearside Biomedical, Inc. has completed its delisting from The Nasdaq Stock Market LLC and transferred trading to the OTC Pink Limited Market following its Chapter 11 bankruptcy filing.

Summary

• Clearside Biomedical, Inc. (CLSD) filed a Form 25 with the U.S. Securities and Exchange Commission (SEC) on December 8, 2025, to finalize its delisting from The Nasdaq Stock Market LLC.
• The delisting was a direct consequence of the company's voluntary petition for relief under Chapter 11 of the Bankruptcy Code (Case No. 25-12109) in the United States Bankruptcy Court for the District of Delaware.
• Trading of the Common Stock on Nasdaq was suspended effective December 1, 2025.
• The Common Stock began trading on the OTC Pink Limited Market on December 1, 2025, under the symbol CLSDQ.
• The Form 25 will also serve to deregister the Common Stock under Section 12(b) of the Securities Exchange Act of 1934, effective 90 days after the Form 25 becomes effective, which will reduce certain SEC reporting obligations.

Sentiment

Score: 1

Explanation: The filing details a series of highly negative events including delisting from a major exchange, transfer to an illiquid market, and a Chapter 11 bankruptcy filing, indicating severe financial distress and a significant loss of value for shareholders.

Negatives

• Delisting of Common Stock from The Nasdaq Stock Market LLC.
• Suspension of trading on Nasdaq effective December 1, 2025.
• Transfer of trading to the OTC Pink Limited Market, which typically implies significantly reduced liquidity and transparency for investors.
• Filing of a voluntary petition for relief under Chapter 11 of the Bankruptcy Code, indicating severe financial distress.
• Termination of registration under Section 12(b) of the Exchange Act, which will lead to reduced public disclosure and transparency.

Risks

• Uncertainty regarding the timing and outcome of the bankruptcy filing.
• Uncertainty regarding the length of time the company will operate under Chapter 11 of the Bankruptcy Code.
• Risk concerning the continued availability of operating capital during the pendency of Chapter 11 proceedings.
• Potential negative impact of the bankruptcy filing and expected filings of Form 25 and Form 15 on the trading price and volatility of the company's common stock.
• Uncertainty regarding the timing or amount of any distributions, if any, to the company's stakeholders.

Future Outlook

The company's forward-looking statements primarily concern the timing and process of its delisting and deregistration, acknowledging significant risks and uncertainties related to the bankruptcy proceedings and their potential impact on operations and stakeholders. The company does not intend to update these statements unless required by law.

Management Comments

• The company assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Industry Context

This announcement reflects a company-specific financial distress scenario rather than a broader industry trend. While the biotechnology and pharmaceutical sectors can be capital-intensive and prone to clinical trial risks, Clearside Biomedical's delisting and bankruptcy filing appear to be the culmination of internal operational and financial challenges, leading to a loss of investor confidence and exchange compliance.

Legal Proceedings

• Voluntary petition for relief under Chapter 11 of the Bankruptcy Code (Case No. 25-12109) in the United States Bankruptcy Court for the District of Delaware.

Stakeholder Impact

• Shareholders: Significant negative impact due to delisting from Nasdaq, transfer to OTC Pink (reduced liquidity, transparency), and the Chapter 11 bankruptcy filing, which typically results in substantial or complete loss of equity value.
• Creditors: Impacted by the Chapter 11 bankruptcy proceedings, which will determine the timing and amount of any distributions.
• Employees: Potential impact on job security and benefits due to bankruptcy proceedings, though not explicitly stated in the filing.

Next Steps

• The Company Form 25 will become effective no earlier than December 18, 2025, completing the delisting from Nasdaq.
• Deregistration of the Common Stock under Section 12(b) of the Exchange Act will become effective 90 days after the Form 25 becomes effective.
• The company will continue to operate under Chapter 11 of the Bankruptcy Code, with its timing and outcome subject to considerable risks and uncertainties.

Key Dates

Recommendation

The company's delisting from Nasdaq, transfer to the OTC Pink market, and filing for Chapter 11 bankruptcy protection signal severe financial distress and a high probability of significant or complete loss of shareholder value. Investors should exit their positions immediately if possible, as the equity is likely to be worthless or nearly worthless in bankruptcy proceedings.

Keywords

Clearside Biomedical, CLSD, CLSDQ, Nasdaq delisting, Chapter 11 bankruptcy, OTC Pink, Form 8-K, SEC filing, corporate governance, financial distress